AEZS Aeterna Zentaris Inc.

0.88
+0.015  (2%)
Previous Close 0.86
Open 0.85
Price To book 2.22
Market Cap 12.54M
Shares 14,333,000
Volume 176,326
Short Ratio 2.93
Av. Daily Volume 342,352

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 4, 2017 - trial failed. Announced March 30, 2017 intention to file NDA 3Q 2017.
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
Phase 3 trial did not meet primary endpoint - May 1, 2017.
Zoptrex
Endometrial cancer

Latest News

  1. Is the Options Market Predicting a Spike in Aeterna Zentaris (AEZS) Stock?
  2. Aeterna Zentaris Announces Election of Directors at 2017 Shareholders' Meeting
  3. Aeterna Zentaris reports 1Q loss
  4. Aeterna Zentaris Reports First Quarter 2017 Financial and Operating Results
  5. Aeterna Zentaris to Announce First Quarter 2017 Financial and Operating Results on May 8, 2017
  6. Today's Research Reports on Stocks to Watch: AEterna Zentaris and Exelixis
  7. AEterna's stock plunges toward record low after cancer treatment fails in Phase 3 trial
  8. Aeterna Zentaris Announces that ZoptEC Phase 3 Clinical Study of Zoptrex™ Did Not Achieve its Primary Endpoint
  9. Aeterna Zentaris to Announce Top-Line Results of the ZoptEC Phase 3 Clinical Study of Zoptrex™
  10. Aeterna Zentaris Announces Replacement At the Market Issuance Program
  11. Aeterna Zentaris Mails Management Information Circular in Connection with Annual Meeting of Shareholders
  12. Aeterna Zentaris shares surge almost 14% premarket on news of NDA for growth hormone drug
  13. Aeterna Zentaris Intends to File NDA with Respect to Macrilen™ in Third Quarter of 2017
  14. Aeterna Zentaris Announces At the Market Issuance Program
  15. Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 27, 2017
  16. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results
  17. Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen™
  18. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 15, 2017
  19. Aeterna Zentaris Announces Presentation Regarding Macrilen™ at 99th Annual Meeting of the Endocrine Society